Subchondral bone has emerged as a promising therapeutic target in osteoarthritis (OA).61 The microstructural impairment of subchondral bone caused by osteoporosis is a contributing factor to cartilage damage in early osteoarthritis.62,63 Therefore, investigating whether targeting FXR at an early stage of OA could improve subchondral bone quality warrants further exploration. Here, NR1H4 is linked to osteoarthritis.